Showing results (161-170 of 277) with videos related to
Sort By:
Pageof 28
Anais Brasileiros De Dermatologia|August 28, 2015
Use of tumor necrosis factor alpha (TNF α) antagonists in a patient with psoriasis and Chagas diseaseCristián Navarrete-Dechent, Daniela Majerson, Marisa Torres, et al.American Journal of Human Genetics|April 24, 2012
PSORS2 is due to mutations in CARD14Catherine T Jordan, Li Cao, Elisha D O Roberson, et al.Journal of the American Academy of Dermatology|October 15, 2017
Spectrum of orocutaneous disease associations: Genodermatoses and inflammatory conditionsElizabeth G Wilder, Jillian Frieder, Suraj Sulhan, et al.American Journal of Clinical Dermatology|February 26, 2017
Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE StudyCarle Paul, Craig Leonardi, Alan Menter, et al.Archives of Dermatology|August 18, 2010
The effect of narrowband UV-B treatment for psoriasis on vitamin D status during wintertime in IrelandCaitriona Ryan, Benvon Moran, Malachi J McKenna, et al.Journal of the American Academy of Dermatology|June 14, 2002
A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar linesJ Alastair Carruthers, Nicholas J Lowe, M Alan Menter, et al.American Journal of Clinical Dermatology|September 8, 2019
Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II StudyMark G Lebwohl, Andrew Blauvelt, Alan Menter, et al.Journal of the American Academy of Dermatology|March 12, 2010
The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trialAlan Menter, Matthias Augustin, James Signorovitch, et al.Journal of the American Academy of Dermatology|January 3, 2015
Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasisKim Papp, Alan Menter, Bruce Strober, et al.Lancet (London, England)|February 17, 2009
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trialAlice Gottlieb, Alan Menter, Alan Mendelsohn, et al.Pageof 28